Navigation Links
Northwestern Memorial Study Tests Cancer Drug on Scleroderma Patients
Date:3/6/2008

Study Seeks Treatment to Address Skin Hardening Affects of the Devastating Disease

CHICAGO, March 6 /PRNewswire-USNewswire/ -- Physicians at Northwestern Memorial Hospital are studying the effects of an anti-cancer drug to treat patients with scleroderma, a rare, incurable autoimmune rheumatic disease that leads to hardening and tightening of the skin and connective tissues. Scleroderma affects an estimated 300,000 people in the United States and can often attack the lungs, heart, kidneys and intestinal tract, and sometimes lead to death.

The study is the first of its kind to examine if Gleevec, a cancer drug commonly used to treat leukemia, will treat the skin thickness in scleroderma patients by blocking the pathway that causes fibrosis. Patients enrolled in the clinical trial will receive daily oral doses of Gleevec for six months and will be evaluated initially on a weekly basis at Northwestern Memorial, one of only three centers nationwide participating in the study. Others include Johns Hopkins and Boston University Medical Center.

John Varga, MD, rheumatologist at Northwestern Memorial, John and Nancy Hughes Distinguished Professor in Rheumatology at Northwestern University's Feinberg School of Medicine and principal investigator of the study, said this could be a big step forward for people diagnosed with scleroderma. "Based on recent research performed by investigators at the Feinberg School, Gleevec shows potential efficacy in reducing the abnormal skin changes associated with scleroderma."

The exact cause of Scleroderma, a chronic disease most commonly found in women between the ages of 30 and 40, remains unknown. Through continued research, Northwestern Memorial physicians hope to identify treatments to target the disease and improve the quality of life for patients living with Scleroderma.

"We hope that the use of Gleevec for a sustained period of time will decrease the symptoms of skin hardening, and potentially slow the progression of this devastating disease," adds Dr. Varga.

For more information on the scleroderma Gleevec study at Northwestern, contact Julie Johnson, project coordinator, at (312) 503-2338.

About Northwestern Memorial Hospital

Northwestern Memorial Hospital is one of the country's premier academic medical centers and is the primary teaching hospital of the Northwestern University Feinberg School of Medicine. Northwestern Memorial and its Prentice Women's Hospital and Stone Institute of Psychiatry have 897 beds along with 1,424 affiliated physicians and 6,464 employees. Northwestern Memorial is recognized for providing state-of-the-art patient care and exemplary clinical and surgical advancements in the areas of cardiothoracic and vascular care, gastroenterology, neurology and neurosurgery, oncology, organ and bone marrow transplantation, and women's health. Northwestern Memorial received the prestigious 2005 National Quality Health Care Award and is listed in eight specialties in U.S. News & World Report's 2007 rankings for "America's Best Hospitals." For seven years running, Northwestern Memorial has been rated among the nation's "100 Best Companies for Working Mothers" by Working Mother magazine and has been chosen by Chicagoans for more than a decade as their "most preferred hospital" according to the National Research Corporation's annual survey. Northwestern Memorial carries the Magnet status designation in nursing, the highest recognition possible for patient care and nursing excellence.


'/>"/>
SOURCE Northwestern Memorial Hospital
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Northwestern Offers Clinical Research and Regulatory Administration Graduate Certificate Program
2. Northwestern Memorial Transplant Program Initiates New Study
3. Bertrand Study Finds Significant Value in Breast-Specific Gamma Imaging (BSGI) as an Adjunctive Procedure in Breast Diagnostics
4. Study Finds Starion Instruments Tissue Welding Technology Safe and Effective in Parotidectomy Procedures
5. Thomson Healthcare Cancer Profiler Used in Study
6. Pharmacopeia Initiates Second Phase 2 Hypertension Study with PS433540 (DARA)
7. Genetic Variation Associated with Treatment Response in a Clinical Study of a New Atypical Antipsychotic Fiaptatm (iloperidone)
8. CMC, Moffitt Partner to Study Cancer
9. Pharmacopeia Completes Enrollment in Phase 2 Hypertension Study with PS433540 (DARA)
10. Oral Talactoferrin Alfa Improves Overall Survival in Patients With Refractory Non-Small Cell Lung Cancer: Final Phase 2 Study Results Presented at the 8th Annual Targeted Therapies for the Treatment Of Lung Cancer Meeting
11. EndoGastric Solutions(TM) Announces Results of EsophyX(TM) Multi-Center GERD Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/27/2016)... May 27, 2016 According to ... hypertension is driving ambulatory blood pressure monitoring system market ... and their ability to respond to different pressure rates, ... can lead to various cardiovascular disorders such as heart ... These diseases are growing in prevalence each year. WHO ...
(Date:5/27/2016)... NEW YORK , May 27, 2016 ... with biotechs, drug manufacturers, health insurance companies all falling ... very small healthcare companies. While not often talked about, ... The United States is by ... the world. Advanced Medical Isotope Corp. (OTC: ADMD), Nutranomics ...
(Date:5/26/2016)... , May 26, 2016   ... software and analytics, network solutions and technology-enabled ... announced it entered into a strategic channel ... of outpatient software solutions and revenue cycle ... specialty hospitals and rehabilitation clinics to optimize ...
Breaking Medicine Technology:
(Date:5/27/2016)... ... ... W.S. Badger Co. Inc ., the maker of certified organic and ... of the best small businesses for new dads by Fatherly, the digital lifestyle guide ... progressive benefits to new parents on the organization’s 2016 Best Places to Work ...
(Date:5/27/2016)... ... May 27, 2016 , ... ... help educate the many who are unaware of the plight of aphasia. In ... run within the “Stroke Awareness” campaign. , The link between stroke and aphasia ...
(Date:5/27/2016)... ... ... With a team of certified experts, Validation Center is ... GMP accreditation, Validation Center is also a registered authority of the international system ... Validation Center is ISO17025 accredited and only offers its clients the latest technology, ...
(Date:5/26/2016)... ... 26, 2016 , ... Intalere, the healthcare industry leader in ... inaugural Member Conference at the Paris Hotel in Las Vegas, Nev., May 17-20, ... America’s healthcare providers. , The conference was highlighted by the announcement of the ...
(Date:5/26/2016)... ... May 26, 2016 , ... ... has a significant negative impact on long-term patient survival, reports a team of ... published online this week in the Journal of Thoracic and Cardiovascular Surgery, provide ...
Breaking Medicine News(10 mins):